Moreover and importantly, our approach is justified by a considerable amount of recently published data showing that, in clinical settings, the number of CD8+ T cells present in the tumor microenvironment and their activation status, are major parameters in predicting disease progression and response to immunotherapy in cancer patients38,39. Here, CD8A is linked to cancer.